Report cover image

Europe Neurology Clinical Trials Market Size, Share, Trends, Industry Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Value Chain, By Country – Market Forecast, 2025–2034

Published Sep 01, 2025
Length 124 Pages
SKU # PLRS20451536

Description

The u.s. real-time location systems market size is expected to reach USD 11.84 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Real-time Location Systems (RTLS) Market Share, Size, Trends, Industry Analysis Report By Component (Hardware, Software, Services), By Technology, By Application, By Industry Vertical; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Real-time location systems (RTLS) are technologies that automatically identify and track the location of objects or people in real time, typically within a defined physical space such as hospitals, warehouses, manufacturing plants, or airports. RTLS uses various methods, including radio frequency identification (RFID), Wi-Fi, Bluetooth Low Energy (BLE), ultra-wideband (UWB), and infrared, to detect the position of tagged assets or individuals. These systems consist of fixed reference points and mobile tags attached to the items or people being tracked. Data collected from the tags is transmitted to a central server, where software processes it to display real-time locations on digital maps or dashboards.

RTLS enhances operational efficiency, improves safety, and supports decision-making by providing accurate, up-to-the-minute location data. In healthcare, RTLS helps track medical equipment and monitor patient flow, reducing delays and improving care. In logistics and manufacturing, it optimizes inventory management, streamlines workflows, and reduces losses. Security and access control also benefit from RTLS by enabling the monitoring of personnel in restricted areas.

U.S. Real-time Location Systems (RTLS) Market Report Highlights

In terms of component, the hardware segment accounted for a major revenue share in 2024. The dominance is attributed to strong demand for tags, sensors, readers, and access points across various industries such as healthcare, manufacturing, and logistics.

The software segment is projected to grow at a robust pace in the coming years, owing to the rising focus on analytics, automation, and integration.

Based on technology, the RFID segment dominated the revenue share in 2024, as industries such as healthcare, retail, and logistics heavily relied on it for asset and inventory tracking.

In terms of application, the inventory/asset tracking & management dominated the revenue share in 2024 due to RTLS's ability to streamline warehouse operations, reduce inventory errors, and minimize downtime caused by misplaced assets.

Based on industry vertical, the healthcare segment accounted for a major revenue share in 2024 due to RTLS's ability to enhance patient safety, streamline workflows, and improve asset utilization.

The transportation & logistics segment is expected to grow at a rapid pace in the coming years, owing to the rising complexity of global trade, coupled with customer expectations for faster and more reliable deliveries.

A few key players in the U.S. real-time location systems market include AiRISTA Flow; CenTrak, Inc.; Hewlett Packard Enterprise; Impinj, Inc.; Lowry Solutions; PINC Solutions; Savi Technology; TeleTracking Technologies, Inc.; Ubisense Ltd; and Zebra Technologies Corp.

Polaris Market Research has segmented the U.S. real-time location systems market report on the basis of component, technology, application, and industry vertical:

By Component Outlook (Revenue, USD Billion, 2020–2034)

Hardware

Software

Services

By Technology Outlook (Revenue, USD Billion, 2020–2034)

Ultra-Wideband

Wi-Fi

RFID

ZigBee

Infrared

Others

By Application Outlook (Revenue, USD Billion, 2020–2034)

Inventory/Asset Tracking & Management

Personnel Locating & Monitoring

Access Control & Security

Environmental Monitoring

Yard, Dock, Fleet, & Warehouse Management & Monitoring

Supply Chain Management & Automation

Other

By Industry Vertical Outlook (Revenue, USD Billion, 2020–2034)

Transportation & Logistics

Healthcare

Retail

Manufacturing & Processing

Others

Table of Contents

124 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. U.S. Neurology Clinical Trials Market Insights
4.1. Neurology Clinical Trials Market – Market Snapshot
4.2. Neurology Clinical Trials Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. High Prevalence of Neurological Disorders
4.2.1.2. Strong Government and NIH Funding Support
4.2.2. Restraints and Challenges
4.2.2.1. High trial failure rates due to the complexity
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Neurology Clinical Trials Market Trends
4.6. Value Chain Analysis
5. U.S. Neurology Clinical Trials Market, by Phase
5.1. Key Findings
5.2. Introduction
5.2.1. U.S. Neurology Clinical Trials Market, by Phase, 2020–2034 (USD Billion)
5.3. Phase I
5.3.1. U.S. Neurology Clinical Trials Market, by Phase I, by Country, 2020–2034 (USD Billion)
5.4. Phase II
5.4.1. U.S. Neurology Clinical Trials Market, by Phase II, by Country, 2020–2034 (USD Billion)
5.5. Phase III
5.5.1. U.S. Neurology Clinical Trials Market, by Phase III, by Country, 2020–2034 (USD Billion)
5.6. Phase IV
5.6.1. U.S. Neurology Clinical Trials Market, by Phase IV, by Country, 2020–2034 (USD Billion)
6. U.S. Neurology Clinical Trials Market, by Study Design
6.1. Key Findings
6.2. Introduction
6.2.1. U.S. Neurology Clinical Trials Market, by Study Design, 2020–2034 (USD Billion)
6.3. Interventional
6.3.1. U.S. Neurology Clinical Trials Market, by Interventional, by Country, 2020–2034 (USD Billion)
6.4. Observational
6.4.1. U.S. Neurology Clinical Trials Market, by Observational, by Country, 2020–2034 (USD Billion)
6.5. Expanded Access
6.5.1. U.S. Neurology Clinical Trials Market, by Expanded Access, by Country, 2020–2034 (USD Billion)
7. U.S. Neurology Clinical Trials Market, by Indication
7.1. Key Findings
7.2. Introduction
7.2.1. U.S. Neurology Clinical Trials Market, by Indication, 2020–2034 (USD Billion)
7.3. Alzheimer’s Disease
7.3.1. U.S. Neurology Clinical Trials Market, by Alzheimer’s Disease, by Country, 2020–2034 (USD Billion)
7.4. Depression (MDD)
7.4.1. U.S. Neurology Clinical Trials Market, by Depression (MDD), by Country, 2020–2034 (USD Billion)
7.5. Parkinson's Disease (PD)
7.5.1. U.S. Neurology Clinical Trials Market, by Parkinson's Disease (PD), by Country, 2020–2034 (USD Billion)
7.6. Epilepsy
7.6.1. U.S. Neurology Clinical Trials Market, by Epilepsy, by Country, 2020–2034 (USD Billion)
7.7. Stroke
7.7.1. U.S. Neurology Clinical Trials Market, by Stroke, by Country, 2020–2034 (USD Billion)
7.8. Traumatic Brain Injury (TBI)
7.8.1. U.S. Neurology Clinical Trials Market, by Traumatic Brain Injury (TBI), by Country, 2020–2034 (USD Billion)
7.9. Amyotrophic Lateral Sclerosis (ALS)
7.9.1. U.S. Neurology Clinical Trials Market, by Amyotrophic Lateral Sclerosis (ALS), by Country, 2020–2034 (USD Billion)
7.10. Huntington's Disease
7.10.1. U.S. Neurology Clinical Trials Market, by Huntington's Disease, by Country, 2020–2034 (USD Billion)
7.11. Muscle Regeneration
7.11.1. U.S. Neurology Clinical Trials Market, by Muscle Regeneration, by Country, 2020–2034 (USD Billion)
7.12. Others
7.12.1. U.S. Neurology Clinical Trials Market, by Others, by Country, 2020–2034 (USD Billion)
8. U.S. Neurology Clinical Trials Market, by Value Chain
8.1. Key Findings
8.2. Introduction
8.2.1. U.S. Neurology Clinical Trials Market, by Value Chain, 2020–2034 (USD Billion)
8.3. In House
8.3.1. U.S. Neurology Clinical Trials Market, by In House, by Country, 2020–2034 (USD Billion)
8.4. CROs
8.4.1. U.S. Neurology Clinical Trials Market, by CROs, by Country, 2020–2034 (USD Billion)
8.5. Investigator Sites/Clinical Sites
8.5.1. U.S. Neurology Clinical Trials Market, by Investigator Sites/Clinical Sites, by Country, 2020–2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Biogen
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Charles River Laboratories
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Charles River Laboratories
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Eisai Co., Ltd.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. ICON plc
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. IQVIA
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Laboratory Corporation of America Holdings
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Medpace Holdings, Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Parexel
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Pfizer Inc.
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Syneos Health
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. Thermo Fisher Scientific
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.